MedImmune Message Board

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : MedImmune

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next

To: PENNY who wrote (13)	3/29/1997 11:17:00 PM
From: Doug Meetmer	of 416

Penny, The scarcity of Respigam is BAD for the company and the stock. This will undoubtably hurt earnings and I wouldn't be surprised if the stockprice falls. The price of Respigam has much more to do with demand than supply. Respigam is the only game in town and Medimmune has a monopoly on it. The fact that they are running short on supply is a missed opportunity for medimmune to haul in extra cash. Doug

Report TOU Violation

Share This Post

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next